• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cancers, Vol. 12, Pages 599: Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas/Paragangliomas
Luconi Chinopoulos Patocs Pheochromocytoma/paragangliomas (Pheo/PGL) are rare endocrine cancers with strong genetic background. Mutations in the SDHB subunit of succinate dehydrogenase (SDH) predispose patients to malignant disease with limited therapeutic options and poor prognosis. Using a host of cellular and molecular biology techniques in 2D and 3D cell culture formats we show that SDH inhibition had cell line specific biological and biochemical consequences. Based on our studies performed on PC12 (rat chromaffin cell line), Hela (human cervix epithelial cell line), and H295R (human adrenocortical cell li...
Source: Cancers - March 4, 2020 Category: Cancer & Oncology Authors: Sarkadi Meszaros Krencz Canu Krokker Zakarias Barna Sebestyen Papay Hujber Butz Darvasi Igaz Doczi Luconi Chinopoulos Patocs Tags: Article Source Type: research

Expression of PDK1 in malignant pheochromocytoma as a new promising potential therapeutic target
ConclusionWe have demonstrated for the first time that PDK1 is overexpressed in human malignant PCC and plays an important role in the malignant biological behaviors of PC12 cell. Specifically, we have revealed that knockdown of PDK1 could attenuate activation of the Akt signaling. These data suggest that PDK1 could be a new promising potential therapeutic target in human cancer treatment for malignant PCC.
Source: Clinical and Translational Oncology - February 13, 2019 Category: Cancer & Oncology Source Type: research

Enhanced wild-type p53 expression by small activating RNA dsP53-285 induces cell cycle arrest and apoptosis in pheochromocytoma cell line PC12.
Authors: Lin D, Meng L, Xu F, Lian J, Xu Y, Xie X, Wang X, He H, Wang C, Zhu Y Abstract Malignant pheochromocytoma (PHEO) is diagnosed only when metastasis has occurred, making it less likely for patients to obtain the benefits of traditional chemotherapy. Anti-oncogene TP53 mutation has been detected in PHEO and is possibly related to disease progression. However, whether the upregulation of wild-type TP53 has antitumoral effects on PHEO remains completely unknown. In the present study, we used RNA activation (RNAa) technique to upregulate the expression of wild-type TP53 by transfecting synthetic dsP53‑285 into...
Source: Oncology Reports - October 20, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma
Abstract Recent studies have found that mammalian target of rapamycin complex 2 (mTORC2) is emerging as a potential therapeutic target in the treatment of many human cancers. However, the effects of targeting of mTORC2 on malignant pheochromocytomas (PCC) and paragangliomas (PGL) have not been reported. The aim of the study was to investigate the effects of targeting of mTORC2 on malignant PCC/PGL by comparing the inhibitory effects of targeting of mTORC2 with mTORC1 on pheochromocytoma PC12 cell in vitro and vivo. The expressions of regulatory-associated protein of mTOR (raptor) and rapamycin-insensitive companio...
Source: Tumor Biology - February 10, 2015 Category: Cancer & Oncology Source Type: research

Abstract 4059: The bone morphogenic protein 7 (Bmp7) plays a pro-tumorigenic role in pheochromocytoma
Conclusions In conclusion, we demonstrated for the first time that Bmp7 promotes the migration and invasion of PCC cells. We found that endogenous Bmp7 levels are influenced by the amount of p27. Integrin beta1 seems to mediate the ability of Bmp7 signaling to promote migration and invasion of PCC cells. Bmp7 represents a novel target for therapy of PCC since the knock-down in vitro shows promising impairment of the tumorigenic phenotype. Citation Format: Ines Leinhäuser, Ines Höfig, Natasa Anastasov, Felix Beuschlein, Massimo Mannelli, Michael J. Atkinson, Natalia S. Pellegata. The bone morphogenic protein 7 (Bmp7) play...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Leinhauser, I., Hofig, I., Anastasov, N., Beuschlein, F., Mannelli, M., Atkinson, M. J., Pellegata, N. S. Tags: Tumor Biology Source Type: research

Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy.
CONCLUSIONS: The enrichment results and functional example imply that cellular models of chemotherapeutic toxicity may capture components of the underlying polygenic architecture of related traits in patients. PMID: 23204130 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - November 30, 2012 Category: Cancer & Oncology Authors: Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman L, Nakamura Y, Ratain MJ, Kroetz D, Cox NJ, Dolan ME Tags: Clin Cancer Res Source Type: research